FDA Classifies Disc Replacement Surgery Tools as Class II
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting orthopedic manual surgical tools used with total disc replacement devices into a special safety category called Class II. This means these tools will have clear safety rules to follow, making sure they work well and keep patients safe. This change helps doctors get better tools faster without extra red tape, benefiting patients and the medical community alike.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Tools Reclassified to Class II
If you or a family member needs a total disc replacement, the FDA is classifying the manual surgical instruments used with those devices as Class II (special controls). This classification adds codified safety and effectiveness requirements intended to provide reasonable assurance that the tools work safely.
Regulatory Burden Reduced for Makers
If you make or sell orthopedic manual surgical instruments for total disc replacement devices, the FDA says this Class II classification includes special controls and will reduce regulatory burdens. The agency says this change will help enhance patients' access to innovative devices by reducing those burdens.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-16038, Medical Devices; Immunology and Microbiology Devices; Classification of the Mutation Detection Test for Myeloproliferative Neoplasms
The FDA is officially putting mutation detection tests for certain blood cancers into a safer, middle-level category called Class II. This change helps make sure the tests work well and are safe, while also making it easier and faster for patients to get these important tests. Labs and companies making these tests should get ready for new rules that balance safety with quicker access, saving time and possibly money.
Next: 2025-16040, Medical Devices; Orthopedic Devices; Classification of Orthopedic Manual Surgical Instrumentation for Use With Non-Fusion Spinous Process Spacer Devices
The FDA is officially classifying certain surgical tools used with non-fusion spinous process spacers as Class II devices, meaning they’ll follow special safety rules. This change helps make sure these tools are safe and effective while making it easier for patients to get new, helpful treatments. Doctors, device makers, and patients can expect smoother approvals and better access without extra costs or delays.